Courses

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal

This CME program is derived from content presented at the 8th European Stroke Organization Conference (ESOC 2022). This educational activity, chaired by Dr. Thorsten Steiner, will review optimal management strategies of patients with anti-FXa-DOAC-associate Intracranial Hemorrhage (ICH). The worldwide utilization of DOACs for a number of different indications has continuously increased over the past decade, and while the anti-FXa DOACS ...
View Course
Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. In module 3, Dr. George Bakris will analyze the clinical trial data for newer therapeutic options to treat patients with hyperkalemia. Following, Dr. Matthew Weir will lead a faculty discussion to further delve into these trials and how they relate to patient care. Next, ...
View Course

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. Starting with module 1, Dr. Biff Palmer will review the science of recurrent hyperkalemia, including relationships between dietary potassium intake, serum potassium, and patient morbidities. Next, in module 2, Dr. Pamela Kushner will evaluate the limitations and impact of plant-based diets and potassium restricted ...
View Course

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis

This CME program will highlight recent advances in the treatment and management of patients with myasthenia gravis (MG). The expert faculty, Dr. James F. Howard Jr., will first outline the pathophysiology and disease course of MG, referencing the impact of treatment and disease burden on patients. Following, current clinical trial data, including that of complement inhibitor therapies in generalized myasthenia ...
View Course
Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations

Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. William Corrao, will first highlight strategies for early diagnosis and classification of chronic obstructive pulmonary disease (COPD), referencing the current Gold Guidelines. Following, current clinical trial data will be reviewed, and clinical relevance debated in an interactive panel format. Dr. Corrao will ...
View Course
Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics

Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Gregory Tino, will first outline the pathophysiology, prevalence and radiological distribution of non-cystic fibrosis bronchiectasis (NCFBE). Current treatment guidelines and recommendations for patients with NCFBE will be reviewed and an overview of phenotyping provided. Dr. Tino will conclude with an analysis of ...
View Course
Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Anne O’Donnell, will first outline both the prevalence and pathophysiology of non-tuberculin mycobacterial lung disease (NTM-LD). Following, current clinical trial data for mycobacterium avium complex (MAC) will be reviewed and clinical relevance debated, including a conversation of toxicities and challenges for clinicians ...
View Course
An Update on the Assessment and Therapeutic Management of Cognitive Decline in Patients with Multiple Sclerosis

An Update on the Assessment and Therapeutic Management of Cognitive Decline in Patients with Multiple Sclerosis

This CME program will provide an update on the assessment and therapeutic management of cognitive decline in patients with multiple sclerosis (MS). The expert faculty, Dr. Ann Bass, will first cover multiple sclerosis cognition dysfunction in the modern treatment era, highlighting various measurement tools. Following, recent clinical trial data regarding treatment and prevention of cognitive decline will be reviewed, including ...
View Course
Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

This CME/CE program will provide clinicians with an update on treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty will review the importance of the role of the diabetes care and education specialist to minimize glucose variability in patients on longer-acting insulins. Next, a clinical review of newer longer-acting ...
View Course

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

This CME program will highlight treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty, Dr. Neil S. Skolnik, will outline the importance of improving patients’ glucose to time-in-range, minimize glucose variability, and incorporate continuous glucose monitoring in patients with diabetes. Following, Dr. Skolnik will discuss how to distinguish ...
View Course